ZVSA (ZyVersa Therapeutics) Other Long-Term Liabilities: $0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ZVSA ZyVersa Therapeutics Inc ZVSA
30 GF Score
Price $0.10
! 1 Warning Sign
View Full Analysis

What is ZyVersa Therapeutics Other Long-Term Liabilities?

ZyVersa Therapeutics ZVSA +3.83% 30 Other Long-Term Liabilities is $0.00 Mil as of Mar. 2026. GuruFocus rates ZVSA with a GF Score™ of 30/100. The stock has 1 warning sign investors should review.

ZyVersa Therapeutics's other long-term liabilities for the quarter that ended in Mar. 2026 was $0.00 Mil.

ZyVersa Therapeutics's annual other long-term liabilities increased from Dec. 2023 ($-0.00 Mil) to Dec. 2024 ($0.00 Mil) but then declined from Dec. 2024 ($0.00 Mil) to Dec. 2025 ($0.00 Mil).

ZyVersa Therapeutics Other Long-Term Liabilities Related Terms

ZyVersa Therapeutics Other Long-Term Liabilities Historical Data

* Premium members only.

The historical data trend for ZyVersa Therapeutics's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ZyVersa Therapeutics Other Long-Term Liabilities Chart

ZyVersa Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Long-Term Liabilities
Get a 7-Day Free Trial 0.00 0.00 -0.00 0.00 0.00

ZyVersa Therapeutics Quarterly Data
Dec20 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.00 -0.00 0.00 0.00 0.00
ZVSA
30GF Score
ZyVersa Therapeutics Inc ZVSA
Other Long-Term Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ZyVersa Therapeutics Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

What does a Other Long-Term Liabilities of $0.00 Mil mean?
ZyVersa Therapeutics (ZVSA) has a Other Long-Term Liabilities of $0.00 Mil as of Mar. 2026. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on ZyVersa Therapeutics and its competitors.
Is ZyVersa Therapeutics' Other Long-Term Liabilities too high?
ZyVersa Therapeutics' current Other Long-Term Liabilities is $0.00 Mil. Overall, ZyVersa Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does ZyVersa Therapeutics' Other Long-Term Liabilities compare to AGTX and CERO?
ZyVersa Therapeutics' Other Long-Term Liabilities of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long-Term Liabilities for a Biotechnology company?
A good Other Long-Term Liabilities depends on the Biotechnology industry context. However, Other Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long-Term Liabilities mean?
A high Other Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on ZyVersa Therapeutics and its competitors. ZyVersa Therapeutics's current Other Long-Term Liabilities is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ZyVersa Therapeutics stock overvalued right now?
ZyVersa Therapeutics (ZVSA) has a current Other Long-Term Liabilities of $0.00 Mil. The current Other Long-Term Liabilities is $0.00 Mil. ZyVersa Therapeutics' overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long-Term Liabilities calculated?
Other Long-Term Liabilities is calculated from a company's financial statements. For ZyVersa Therapeutics (ZVSA), the current Other Long-Term Liabilities is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

ZyVersa Therapeutics Business Description

Address 2200 North Commerce Parkway, Suite 208, Weston, FL, USA, 33326
ZyVersa Therapeutics Inc is a clinical-stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The company has two proprietary globally licensed drug development platforms which are Cholesterol Efflux MediatorTM, VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is an injectable drug in clinical development for the treatment of renal diseases. and IC 100 is a monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of inflammatory conditions.
30GF Score

Get the complete analysis for ZVSA

Other Long-Term Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.10
Price